Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corbus Pharmaceuticals

6.79
+0.37005.76%
Post-market: 6.790.00000.00%18:49 EDT
Volume:136.00K
Turnover:921.26K
Market Cap:83.06M
PE:-1.84
High:6.90
Open:6.51
Low:6.47
Close:6.42
Loading ...

Company Profile

Company Name:
Corbus Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
28
Office Location:
500 River Ridge Drive,Norwood,Massachusetts,United States
Zip Code:
02062
Fax:
617 663 6085
Introduction:
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Directors

Name
Position
Alan Holmer
Director (Chairman of the Board)
Yuval Cohen
Chief Executive Officer and Director
Avery W. Catlin
Director
David P. Hochman
Director
Renu Gupta
Director

Shareholders

Name
Position
Yuval Cohen
Chief Executive Officer and Director
Sean Moran
Chief Financial Officer
Barbara White
Chief Medical Officer
Mark Tepper
President and Chief Scientific Officer